- Home
- SRZN vs SNTI Comparison
SRZN vs SNTI Comparison
Compare SRZN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- SNTI
- Stock Information
- Founded
- SRZN 2015
- SNTI 2016
- Country
- SRZN United States
- SNTI United States
- Employees
- SRZN N/A
- SNTI N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- SNTI Health Care
- Exchange
- SRZN Nasdaq
- SNTI Nasdaq
- Market Cap
- SRZN 82.8M
- SNTI 85.3M
- IPO Year
- SRZN N/A
- SNTI N/A
- Fundamental
- Price
- SRZN $7.10
- SNTI $3.18
- Analyst Decision
- SRZN Strong Buy
- SNTI Strong Buy
- Analyst Count
- SRZN 2
- SNTI 1
- Target Price
- SRZN $38.50
- SNTI $12.00
- AVG Volume (30 Days)
- SRZN 11.0K
- SNTI 226.4K
- Earning Date
- SRZN 05-09-2025
- SNTI 05-06-2025
- Dividend Yield
- SRZN N/A
- SNTI N/A
- EPS Growth
- SRZN N/A
- SNTI N/A
- EPS
- SRZN N/A
- SNTI N/A
- Revenue
- SRZN $11,638,000.00
- SNTI N/A
- Revenue This Year
- SRZN N/A
- SNTI N/A
- Revenue Next Year
- SRZN N/A
- SNTI N/A
- P/E Ratio
- SRZN N/A
- SNTI N/A
- Revenue Growth
- SRZN N/A
- SNTI N/A
- 52 Week Low
- SRZN $6.00
- SNTI $1.52
- 52 Week High
- SRZN $18.17
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- SRZN 31.40
- SNTI 43.69
- Support Level
- SRZN $9.96
- SNTI $3.10
- Resistance Level
- SRZN $11.56
- SNTI $3.61
- Average True Range (ATR)
- SRZN 0.96
- SNTI 0.30
- MACD
- SRZN -0.29
- SNTI -0.04
- Stochastic Oscillator
- SRZN 21.20
- SNTI 40.28
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.